DS
ARQT icon

David Shaw’s Arcutis Biotherapeutics ARQT Stock Holding History

David Shaw’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104M Buy
3,949,609
+1,453,387
+58% +$33.9M 0.05% 435
2026
Q1 		$58.8M Sell
2,496,222
-186,865
-7% -$4.77M 0.04% 585
2025
Q4 		$77.9M Buy
2,683,087
+564,374
+27% +$14.4M 0.04% 507
2025
Q3 		$39.9M Sell
2,118,713
-44,288
-2% -$698K 0.02% 769
2025
Q2 		$30.3M Buy
2,163,001
+173,493
+9% +$2.43M 0.02% 808
2025
Q1 		$31.1M Sell
1,989,508
-524,069
-21% -$7.38M 0.03% 701
2024
Q4 		$35M Buy
2,513,577
+768,553
+44% +$8.42M 0.03% 729
2024
Q3 		$16.2M Buy
1,745,024
+737,640
+73% +$7.28M 0.01% 1118
2024
Q2 		$9.37M Buy
1,007,384
+790,518
+365% +$7.15M 0.01% 1377
2024
Q1 		$2.15M Buy
+216,866
New +$1.62M ﹤0.01% 2579
2023
Q2 		– Sell
-10,629
Closed -$117K – 4219
2023
Q1 		$117K Sell
10,629
-26,547
-71% -$384K ﹤0.01% 3968
2022
Q4 		$550K Sell
37,176
-37,200
-50% -$650K ﹤0.01% 3808
2022
Q3 		$1.42M Buy
+74,376
New +$1.69M ﹤0.01% 3308
2020
Q3 		– Sell
-9,546
Closed -$289K – 3814
2020
Q2 		$289K Buy
+9,546
New +$276K ﹤0.01% 3642

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

David Shaw's ARQT Position: Q2 2026 in Review

David Shaw increased its Arcutis Biotherapeutics (ARQT) stake by 58% in Q2 2026, buying an estimated $33.9M and bringing the position to 3,949,609 shares worth $104M. The position accounts for 0.05% of the portfolio, ranked #435.

David Shaw first reported a position in ARQT in Q2 2020 and has held it in 14 quarters since. 271 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • David Shaw held 3,949,609 shares of Arcutis Biotherapeutics worth $104M as of Q2 2026.
  • David Shaw bought 1,453,387 Arcutis Biotherapeutics shares in Q2 2026, an estimated $33.9M.
  • Arcutis Biotherapeutics made up 0.05% of David Shaw's portfolio in Q2 2026, its #435 holding.
  • David Shaw first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 14 quarters since.
  • 271 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.